Brian Gormley

Healthcare investor says it has helped founders start more than 60 businesses since 2018.

Dimension has raised $500 million for its second venture fund targeting startups at the intersection of technology and life sciences as researchers increasingly apply tools such as artificial intelligence to biomedical research. 

President-elect Trump’s choice to head the Department of Health and Human Services is a proponent of using healthful foods to fight disease.

Investor Alcon Research is suing portfolio company Aurion Biotech to stop it from pursuing an IPO.

Investors and entrepreneurs will track decisions affecting drugs, medical devices and telehealth.

Venture capitalists and startups in reproductive health are scenario planning for how the U.S. presidential election could affect abortion services and other sectors in the field.

For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs rise. Newly formed Dash Bio says it has a solution. 

With its fourth fund, KdT will continue to make bets on startups that apply data, technology to healthcare and other sectors.

The company’s upsized offering is a hopeful sign for venture investors in the sector.

A legal requirement for an in-person doctor visit to receive a controlled substance was waived in the pandemic. The waiver expires at the end of this year, and telehealth companies are fighting to hang on to it.

The number of deals for $100 million or more have put biotech on pace to come close to full-year 2021’s record total, industry data show.

Exclusive | Medical-Robotics Startup Mendaera Raises $73 Million for Market Launch

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.

The performance of newly public entrants in coming weeks will color other startups’ decisions on whether to take the plunge themselves.

Exclusive | Edge Medical Ventures Opens New Offices, Raises Capital Toward First Fund

Exclusive | EGenesis Raises $191 Million for Transplants of Genetically Edited Pig Organs

For decades cancer drugmakers have taken a more-is-more model when dosing drugs in clinical trials. U.S. regulators want them to reconsider that approach.

The firm connects patients with healthcare professionals who help them negotiate an increasingly complex medical system.

The firm connects patients with healthcare professionals who help them negotiate an increasingly complex medical system.

A noninvasive technology that uses sound waves to destroy tumors gets a tailwind from VC interest in late-stage medtechs.